Clinical trials: Rituximab, completed
T-Cell Peripheral Lymphoma, Gamma Delta Hepatosplenic T-Cell Lymphoma
Phase 1 Trial of Siplizumab and Dose-Adjusted EPOCH-Rituximab in T- and NK-Cell Lymphomas
Studies conducted at the National Cancer Institute suggest that certain chemotherapy drugs may be more effective if given by continuous infusion into the vein rather than by the standard method of rapid intravenous injection.
- Conditions
- T-Cell Peripheral Lymphoma, Gamma Delta Hepatosplenic T-Cell Lymphoma, Subcutaneous Panniculitis-Like T-Cell Lymphoma, NK T-Cell Lymphoma
- Trial name
- NCT01445535
- Testing
- Rituximab, Etoposide, Siplizumab
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- National Cancer Institute (NCI)
Rheumatoid Arthritis
Extension Study to Assess the Efficacy and Safety of Repeat Treatment With Rituximab (MabThera) in Participants With Active Rheumatoid Arthritis (RA)
This study will assess the long-term safety and efficacy of repeat treatment courses of rituximab, in combination with methotrexate in a disease-modifying anti-rheumatic drug (DMARD) inadequate responder population of…
- Trial name
- NCT02093026
- Testing
- Rituximab, Methotrexate, Methylprednisolone
- Where
- 92 sites in United States, Australia and 14 more
- Volunteers
- 465 people
- Sponsor
- Hoffmann-La Roche
Adult Patients With Newly Diagnosed or Relapsed or Refractory Primary Central Nervous System Lymphoma (PCNSL), Or Relapsed or Refractory Secondary Central Nervous System Lymphoma (SCNSL)
Bruton's Tyrosine Kinase (BTK) Inhibitor, Ibrutinib, in Patients With Newly Diagnosed or Refractory/Recurrent Primary Central Nervous System Lymphoma (PCNSL) and Refractory/Recurrent Secondary Central Nervous System Lymphoma (SCNSL)
The purpose of this study is to test any good or bad effects of the study drug called of ibrutinib (also known as Imbruvica™). At this stage of this trial, the study is investigating whether Ibrutinib can be incorporated into the…
- Trial name
- NCT02315326
- Testing
- Ibrutinib, HD- Methotrexate (MTX), Rituximab + HD- Methotrexate (MTX)
- Where
- 7 sites in United States
- Volunteers
- 93 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Lymphoma
S0014 Combination Chemotherapy Plus Rituximab and Radiation Therapy in Treating Patients With Stage I or Stage II Non-Hodgkin's Lymphoma
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Monoclonal antibodies, such as rituximab, can locate cancer cells and either kill them or deliver…
- Trial name
- NCT00005089
- Testing
- rituximab, cyclophosphamide, doxorubicin hydrochloride
- Where
- 92 sites in United States
- Volunteers
- 71 people
- Sponsor
- SWOG Cancer Research Network
Lymphoma
Rituximab in Treating Patients With Waldenstrom's Macroglobulinemia
RATIONALE: Monoclonal antibodies such as rituximab can locate cancer cells and deliver tumor-killing substances to them without harming normal cells.
- Trial name
- NCT00005609
- Testing
- rituximab
- Where
- 69 sites in United States, Puerto Rico and 1 more
- Sponsor
- Eastern Cooperative Oncology Group
Lymphoma
Study of Rituximab-HCVAD Alternating With Rituximab-Methotrexate-Cytarabine Versus Standard Rituximab-CHOP Every 21 Days for Patients With Newly Diagnosed High Risk Aggressive B-Cell Non-Hodgkin's Lymphomas in Patients 60 Years Old or Younger
The overall goal of this clinical research study was to find out which of two different chemotherapy drug combinations, R-CHOP and R-HCVAD, is more effective in treating B-cell lymphoma.
- Trial name
- NCT00290498
- Testing
- Rituximab, Cyclophosphamide, Doxorubicin
- Where
- United States
- Volunteers
- 67 people
- Sponsor
- M.D. Anderson Cancer Center
Systemic Lupus Erythematosus
Cyclophosphamide and Rabbit Antithymocyte Globulin (rATG)/Rituximab in Patients With Systemic Lupus Erythematosus
This study is designed to examine whether treating patients with lupus with high dose cyclophosphamide together with rATG/rituximab (drugs which reduce the function of the immune system), followed by return of their previously…
- Trial name
- NCT00278538
- Testing
- Hematopoietic stem cell transplantation
- Where
- 2 sites in United States
- Volunteers
- 32 people
- Sponsor
- Northwestern University
EBV-induced Lymphomas, EBV-associated Malignancies
Therapeutic Effects of Epstein-Barr Virus Immune T-Lymphocytes Derived From a Normal HLA-Compatible Or Partially-Matched Third-Party Donor in the Treatment of EBV Lymphoproliferative Disorders and EBV-Associated Malignancies
This is a Phase II trial to evaluate the efficacy and safety of human leukocyte antigen (HLA) partially-matched third-party allogeneic Epstein-Barr virus cytotoxic T lymphocytes (EBV-CTLs) for the treatment of EBV-induced…
- Conditions
- EBV-induced Lymphomas, EBV-associated Malignancies, Transplant Patients With EBV Viremia at High Risk for Developing a Recurrent EBV Lymphoma
- Trial name
- NCT01498484
- Testing
- EBV-specific T cells (EBV-CTLs)
- Where
- United States
- Volunteers
- 87 people, healthy volunteers welcome
- Sponsor
- Atara Biotherapeutics
Lymphocytic Leukemia, Chronic
An Observational Study on the Safety Profile of MabThera/Rituxan (Rituximab) in Combination With Chemotherapy in Patients With B Cell-lineage Chronic Lymphocytic Leukaemia (MABERYC)
This prospective observational study will evaluate the safety of MabThera/Rituxan (rituximab) in combination with chemotherapy in patients with previously untreated or relapsed/refractory B cell-lineage chronic lymphocytic…
- Trial name
- NCT01224093
- Testing
- Chemotherapy, rituximab [MabThera/Rituxan]
- Where
- 55 sites in Spain
- Volunteers
- 219 people
- Sponsor
- Hoffmann-La Roche
Rheumatoid Arthritis
Rheumatoid Arthritis Extension Trial For Subjects Who Have Participated In Other PF-05280586 Trials (REFLECTIONS B328-04)
This extension study will evaluate the safety (including immunogenicity) of treatment with rituximab-Pfizer, as well as the safety and immunogenicity after transitioning from rituximab-US or rituximab-EU to rituximab-Pfizer.
- Trial name
- NCT01643928
- Testing
- Rituximab-Pfizer (PF-05280586) x 3 courses, Rituximab-EU+ Rituximab-Pfizer x 2 Courses, Rituximab-US + Rituximab-Pfizer x 2 Courses
- Where
- 71 sites in United States, Australia and 8 more
- Volunteers
- 185 people
- Sponsor
- Pfizer
Follicular Lymphoma
A Trial Looking at Rituximab and Chemotherapy as a Treatment for Follicular Lymphoma in Elderly Patients
The purpose of this study is to determine whether R-FC is more beneficial that R-CVP in the treatment of older patients (aged 60 or over) with Follicular Lymphoma (FL).
- Trial name
- PACIFICO (NCT01303887)
- Testing
- Rituximab, Cyclophosphamide, Vincristine
- Where
- 73 sites in United Kingdom
- Volunteers
- 680 people
- Sponsor
- University of Liverpool
Primary Central Nervous System Lymphoma (PCNSL), Secondary Central Nervous System Lymphoma (SCNSL)
Ibrutinib With Rituximab and Lenalidomide for Patients With Recurrent/Refractory Primary or Secondary Central Nervous System Lymphoma (PCNSL/SCNSL)
The investigator's want to find out if treatment with ibrutinib, rituximab, and lenalidomide are safe and better than the usual approach in patients with recurrent or refractory central nervous system lymphoma.
- Trial name
- NCT03703167
- Testing
- Ibrutinib, Lenalidomide, Rituximab
- Where
- 7 sites in United States
- Volunteers
- 25 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
CD20 Positive, Recurrent B-Cell Non-Hodgkin Lymphoma
Ipilimumab and Rituximab in Treating Patients With Relapsed or Refractory B-cell Lymphoma
This partially randomized phase I trial studies the side effects and best dose of ipilimumab when given together with rituximab in treating patients with B-cell lymphoma that has returned or has not responded to treatment.
- Conditions
- CD20 Positive, Recurrent B-Cell Non-Hodgkin Lymphoma, Refractory B-Cell Non-Hodgkin Lymphoma
- Trial name
- NCT01729806
- Testing
- Ipilimumab, Laboratory Biomarker Analysis, Rituximab
- Where
- 7 sites in United States
- Volunteers
- 32 people
- Sponsor
- National Cancer Institute (NCI)
Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Lymphoma (SLL)
Study of AMD3100 (Plerixafor) and Rituximab in Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
The purpose of this research study is to determine if plerixafor can make CLL/SLL (Chronic Lymphocytic Leukemia/ Small Lymphocytic Lymphoma) cells more sensitive to being killed by rituximab, an anti-cancer drug that is commonly…
- Trial name
- NCT00694590
- Testing
- plerixafor
- Where
- 3 sites in United States
- Volunteers
- 24 people
- Sponsor
- Genzyme, a Sanofi Company
Malignancy, Non-hodgkin Lymphoma
A Phase 1/2 Study of CYT-0851 in B-Cell Malignancies and Advanced Solid Tumors
This clinical trial is an interventional, active-treatment, open-label, multi-center, Phase 1/2 study. The study objectives are to assess the safety, tolerability and pharmacokinetics (PK) of CYT-0851 in patients with…
- Conditions
- Malignancy, Non-hodgkin Lymphoma, Multiple Myeloma, Breast Cancer
- Trial name
- NCT03997968
- Testing
- CYT-0851, CYT-0851 in combination with gemcitabine, CYT-0851 in combination with capecitabine
- Where
- 16 sites in United States
- Volunteers
- 169 people
- Sponsor
- Cyteir Therapeutics, Inc.
Diffuse Large B-Cell Lymphoma
An Observational Study of MabThera/Rituxan (Rituximab) Plus Chemotherapy As First-Line Treatment in Patients With Diffuse Large B-Cell Lymphoma or Follicular Lymphoma
This observational study will evaluate the safety and efficacy of MabThera/Rituxan (rituximab) plus chemotherapy as first-line treatment in patients with diffuse large B-cell lymphoma (DLBCL) or follicular lymphoma (FL).
- Trial name
- NCT01340443
- Where
- 24 sites in China
- Volunteers
- 314 people
- Sponsor
- Hoffmann-La Roche
Leukemia, Lymphoma
Pentostatin, Alemtuzumab, and Rituximab in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
RATIONALE: Drugs used in chemotherapy, such as pentostatin, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00669318
- Testing
- alemtuzumab, rituximab, pentostatin
- Where
- 3 sites in United States
- Volunteers
- 41 people
- Sponsor
- Mayo Clinic
Leukemia, Lymphoma
Infusion of Allogeneic Umbilical Cord Blood-Derived Cluster of Differentiation Antigen 19 (CD19)-Specific T Cells
The goal of this clinical research study is to learn if an infusion of white blood cells (called T cells) that have been genetically changed is safe to give patients who have received an umbilical cord blood transplant (UCBT).
- Trial name
- NCT01362452
- Testing
- T-Cell Infusion, Cord Blood Infusion
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- M.D. Anderson Cancer Center
Lymphoma
Rituximab Combined With ESHAP in Patients With Relapse or Refractory Diffuse Large B Cell Lymphoma (DLBCL)
The purpose of this study is to evaluate the efficacy and toxicity of Rituximab combined with ESHAP (etoposide, methylprednisolone, cytarabine, and cisplatin) in the patients with diffuse large B cell lymphoma (DLBCL).
- Trial name
- NCT00568815
- Testing
- Rituximab combined with ESHAP
- Where
- China
- Volunteers
- 31 people, healthy volunteers welcome
- Sponsor
- Fudan University
Chronic Lymphocytic Leukemia, Prolymphocytic Leukemia
Fludarabine Phosphate, Radiation Therapy, and Rituximab in Treating Patients Who Are Undergoing Donor Stem Cell Transplant Followed by Rituximab for High-Risk Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
This phase II trial studies how well fludarabine phosphate with radiation therapy and rituximab followed by donor stem cell infusions work in treating patients with high-risk chronic lymphocytic leukemia (CLL) or small…
- Conditions
- Chronic Lymphocytic Leukemia, Prolymphocytic Leukemia, Recurrent Small Lymphocytic Lymphoma, Refractory Chronic Lymphocytic Leukemia
- Trial name
- NCT00104858
- Testing
- Allogeneic Hematopoietic Stem Cell Transplantation, Cyclosporine, Fludarabine Phosphate
- Where
- 5 sites in United States, Denmark and 1 more
- Volunteers
- 66 people
- Sponsor
- Fred Hutchinson Cancer Center
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.